Mecasermin Tercica.
Author(s): Norman P
Affiliation(s): Norman Consulting, 18 Pink Lane, Burnham, Bucks, UK. peter.norman2@btinternet.com
Publication date & source: 2006-04, Curr Opin Investig Drugs., 7(4):371-80.
Publication type: Review
Tercica, under license from Genentech, has developed and launched mecasermin, recombinant human insulin-like growth factor-1 (rhIGF-1), for the treatment of growth failure in children with primary IGF deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
|